GT MEDICAL TECHNOLOGIES, INC. — SEC Form D Filing
GT MEDICAL TECHNOLOGIES, INC. filed an SEC Form D on July 22, 2026, reporting $50.06M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- July 22, 2026
- Amount reported
- $50.06M
- Round stage
- Series B+
- Industry
- Medical Devices
- Website
- https://gammatile.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients who undergo surgery for operable brain tumors, including newly diagnosed malignant tumors and recurrent tumors, face significant risks of tumor regrowth and side effects from traditional external radiation therapy.
Solution
GT Medical Technologies develops GammaTile®, an implantable, tile-based radiation therapy that is placed during brain tumor removal surgery to deliver targeted radiation directly to the tumor site, reducing tumor regrowth and minimizing side effects.
Why now
Advances in materials science and targeted radiation delivery allow for novel, localized treatments that improve patient outcomes and quality of life immediately following brain tumor surgery, reducing the burden of traditional post-operative radiation.
Verdict
Investors backed this company's Series B+ round based on the clear clinical utility and immediate patient benefit of GammaTile, not the potential for expansive market disruption. They implicitly bet on accelerated adoption within a specific neurosurgical niche due to demonstrated improvements in local tumor control and reduced systemic radiation exposure. The upside was inherently limited by the narrow application within brain tumor treatment, contrasting with broader oncology platforms that address multiple cancer types.
Source: SEC EDGAR Form D filing